The immune system is amazingly complex, precise and synchronised to deliver effective responses against most health insults. Likewise, medical challenges need to be faced with a multidisciplinary, coordinated and target-specific approach.
In 2016, AQuAS (Catalan Agency for Health Quality and Evaluation), defined indicators used to evaluate the clinical and healthcare quality as a measurement instrument used to evaluate or measure specific aspects of the quality of care.
The R&D response to the SARS-CoV-2 outbreak has been massive, promoted by unprecedented funding to support innovative solutions to fight the COVID-19 pandemic.
Across all industries 9 out of 10 start-ups will fail. This staggering statistic doesn’t exactly inspire confidence. In healthcare the failure-rate may not be as detrimental but remains cause for concern. Which begs the question: why do so many start-ups fail?
Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.
On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!
Dr. Solà-Morales has been selected to become one of the professors that will teach in this postgraduate study provided by the IQS (Instituto Químico de Sarrià).